Andreotti Felicita A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer (see also BMS) : apixaban (2012-2013) - BMS-Pfizer : apixaban, cardiovascular metabolism (2012-2013) - Bayer Schering Pharma : aspirin, rivaroxaban (2012-2013-2014) - Eli Lilly : prasugrel (2012-2013-2014) - Amgen : dyslipidemia (2012-2013-2014-2015) - Daiichi Sankyo : edoxaban (2012-2014) - Daiichi Sankyo-Eli Lilly : edoxaban, prasugrel (2013) - Pfizer : apixaban (2014) - BMS : apixaban, cardiovascular metabolism (2014) - Bayer Schering Pharma : aspirin (2015) - Boehringer-Ingelheim : non-vitamin k antagonist oral anticoagulants (2015) - Daiichi Sankyo : non-vitamin k antagonist oral anticoagulants (2015) - Pfizer : non-vitamin k antagonist oral anticoagulants (2015) - BMS-Pfizer : non-vitamin k antagonist oral anticoagulants (2015) Bax Jeroen Nothing to be declared (2014-2015) D - Research funding (departmental or institutional). - Servier : Farma (2012-2013) - Edwards Lifesciences : Heart Valves (2012-2013) - GE Healthcare : Imaging (2012-2013) - Lantheus Inc : Imaging (2012-2013) - Boston Scientific : Pacing (2012-2013) - Medtronic : Pacing (2012-2013) 27/08/2015 Guidelines on NSTE-ACS (version 2015) - Task Force Expert Type of Relationship with Industry For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication. 1/50
50
Embed
Guidelines on NSTE-ACS (version 2015) - Task Force · Guidelines on NSTE-ACS (version 2015) - Task Force Expert Type of Relationship with Industry For ESC Guidelines: The report below
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Andreotti Felicita A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer (see also BMS) : apixaban (2012-2013)
- Boehringer-Ingelheim : non-vitamin k antagonist oral anticoagulants (2015)
- Daiichi Sankyo : non-vitamin k antagonist oral anticoagulants (2015)
- Pfizer : non-vitamin k antagonist oral anticoagulants (2015)
- BMS-Pfizer : non-vitamin k antagonist oral anticoagulants (2015)
Bax Jeroen Nothing to be declared (2014-2015)
D - Research funding (departmental or institutional).- Servier : Farma (2012-2013)
- Edwards Lifesciences : Heart Valves (2012-2013)
- GE Healthcare : Imaging (2012-2013)
- Lantheus Inc : Imaging (2012-2013)
- Boston Scientific : Pacing (2012-2013)
- Medtronic : Pacing (2012-2013)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Task Force
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
1/50
Bax Jeroen - St Jude Medical : Pacing (2012-2013)
- Biotronik : Pacing (2012-2013)
Borger Michael A A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Edwards Lifesciences : heart valve therapy (2012-2013-2014-2015)
- St. Jude Medical : heart valve therapy (2012-2013-2014-2015)
- Sorin Group : heart valve therapy (2013-2014-2015)
D - Research funding (departmental or institutional).- Edwards Lifesciences : heart valve therapy (2015)
Brotons Carlos A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : Apixaban (2012-2013-2014-2015)
- Bayer : Aspirin (2012-2013-2014-2015)
- Astra Zeneca : Brilinta (2014)
- Lundbeck : Selincro (2014-2015)
Chew Derek B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Anti-platelet therapy (2012-2013)
- Abbott Vascular : Mitral Clip (2012-2013)
- Astra Zeneca : Antiplatelet therapy (2014-2015)
- Medscape : Physician Education (2014-2015)
D - Research funding (departmental or institutional).- Astra Zeneca : Anti-platelet therapy (2012-2013)
- Astra Zeneca : Antiplatelet (2014-2015)
Collet Jean-Philippe A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : antiplatelet (2012)
- Eli Lilly : antiplatelet (2012)
- Medco Health Solutions : antiplatelet (2012)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Task Force
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
- DC Devices : REDUC ELAP device trial (2013-2014-2015)
- Astrazeneca : Therapeutic (2013-2014-2015)
- Bayer : Xarelta (2013-2014-2015)
- CVRx : Baroreceptor Stimulation (2015)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Task Force
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
3/50
Hasenfuss Gerd B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Circulite : Assist Device (2012)
- Astra Zeneca : Brilique (2012)
- Bayer : rivaroxaban (2012)
D - Research funding (departmental or institutional).- Servier : RYCALS (2012)
Kjeldsen Keld Per Nothing to be declared (2012-2013-2014-2015)
Lancellotti Patrizio A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boston Scientific : Heart Failure (2012)
- Servier : Heart Failure (2013)
- Abbott : MitraClip (2013)
- Menarini : nebivolol (2014)
- St Jude Medical : Heart Failure (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Brilique (2012)
- Servier : Coversyl (2012)
- Abbott Vascular : MitraClip (2012)
- Astrazeneca : Dyslipidemia (2013)
- Boston Scientific : CRT (2014)
- Servier : procoralan (2014)
- Daiichi Sankyo : Teaching course on imaging (2015)
D - Research funding (departmental or institutional).- Actelion : Pulmonary Hypertension (2013)
Landmesser Ulf A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Cardiovascular Research (2012)
- Roche Pharma : Cardiovascular Research (2012-2013)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Task Force
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
Mueller Christian Eugen A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Alere : Diagnostics (2012)
Guidelines on NSTE-ACS (version 2015) - Task Force
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
5/50
Mueller Christian Eugen - BG medicine : Diagnostics (2013-2014-2015)
Guidelines on NSTE-ACS (version 2015) - Task Force
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
6/50
Mukherjee Debabrata C - Receipt of royalties for intellectual property.- Wolters Kluwer Publishers : Textbook of Cardiology (2012-2013)
- Informa Healthcare Publishers : Textbook of Cardiology (2012-2013)
Patrono Carlo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Ticagrelor, PPI (2012)
- Bayer : Aspirin (2012-2013)
- Eli Lilly : Prasugrel (2012-2013)
- Merck Sharp & Dohme : Vorapaxar (2012-2013)
D - Research funding (departmental or institutional).- Bayer AG : Aspirin (2012-2013-2014-2015)
Roffi Marco A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichi Sankyo : antiplatelet therapy (2012-2013)
- Lilly : antiplatelet therapy (2012-2013)
- Astra Zeneca : antipletelet therapy (2012-2013)
- Johnson & Johnson : coronary catheters (2014)
D - Research funding (departmental or institutional).- Biosensors : devices (2012-2013-2014-2015)
- Boston Scientific : devices (2012-2013-2014-2015)
- Medtronic : devices (2012-2013-2014-2015)
- Biotronik : devices (2012-2013-2014-2015)
- Abbott Vascular : devices (2012-2013-2014-2015)
Storey Robert A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Eisai : Atopaxar (2012)
Guidelines on NSTE-ACS (version 2015) - Task Force
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichi Sankyo : Prasugrel (2012)
- Eli Lilly : Prasugrel (2012)
- Accumetrics : VerifyNow device (2012-2013)
- Astra Zeneca : Ticagrelor (2012-2013-2014-2015)
D - Research funding (departmental or institutional).- Eli Lilly : Prasugrel (2012)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Task Force
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
8/50
Storey Robert - Merck Sharp & Dohme : Vorapaxar (2012)
- Accumetrics : VerifyNow (2012-2013)
- Astra Zeneca : Ticagrelor (2012-2013-2014-2015)
Valgimigli Marco A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Accumetrics : Platlet Function Assay (2012-2013)
D - Research funding (departmental or institutional).- Astra Zeneca : Anti-thrombotic in ACS (2014)
- Astra Zeneca : P2Y12 inhibitor (2015)
Windecker Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Biosensors : Stent (2012)
- Boston Scientific : Stent (2012)
- Cordis : Stent (2012)
- Edwards Lifesciences : TAVI (2012)
- Astra Zeneca : Antiplatelet drug (2012-2013)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Task Force
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
9/50
Windecker Stephan - Eli Lilly : Antiplatelet drug (2012-2013)
- Abbott : Stent (2012-2013)
- Medtronic : Stent (2012-2013)
- Biotronik : Stent (2012-2013)
- Astra Zeneca : Antiplatelet therapy (2014-2015)
- Eli Lilly : Antiplatelet therapy (2014-2015)
- Bayer Healthcare : Antithrombotic drug (2014-2015)
- Abbott : Stent and Heartvalvetherapy (2014-2015)
D - Research funding (departmental or institutional).- Biosensors : Stent (2012)
- Medtronic : Stent (2012)
- Cordis : Stent (2012)
- St Jude Medical : OCT (2012-2013-2014-2015)
- Biotronik : Stent (2012-2013-2014-2015)
- Abbott : Stent (2012-2014-2015)
- Medtronic : Stent and Heartvalves (2014)
- Medicines Company : Antithrombotic therapy (2014-2015)
- Johnson & Johnson : Catheters (2014-2015)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Task Force
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
10/50
Windecker Stephan - Edwards Lifesciences : Heartvalves (2014-2015)
- Boston Scientific : Stent and Heartvalves (2014-2015)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Task Force
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
11/50
Abir-Khalil Saadia A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Novartis : cardiology (2013-2014-2015)
- Pfizer : cardiology (2014-2015)
- Sanofi Aventis : cardiology (2014-2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : cardiology (2013)
- Sanofi Aventis : cardiology (2013)
Achenbach Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : Anticoagulation (2013)
- Behring : Anticoagulation (2013)
- Astra Zeneca : Antiplatelet Therapy (2013)
- Abbott : Coronary Intervention (2013)
- Siemens Healthcare : CT (2013)
- Servier : Imaging (2013)
- Guerbet : Imaging (2013)
D - Research funding (departmental or institutional).- Abbott : Coronary Intervention (2013-2014)
- Siemens Healthcare : Imaging (2013-2015)
Agewall Stefan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Böhringer Ingelheim : Anticoagulatn treatment (2013)
- Roche Diagnostics : Cardiac markers (2013)
- Orion : Heart failure (2013)
- Pfizer : Lipids (2013)
- Sanofi Aventis : Lipids (2013)
- Siemens Healthcare : Markers (2013)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
12/50
Agewall Stefan - Astra Zeneca : Platelet inhibition (2013-2014-2015)
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
14/50
Baigent Colin - Abbott : Fish oil (2014-2015)
- Novartis : LCZ-696 (2014-2015)
- Novartis : Transplantation (2014-2015)
- Pfizer : Transplantation (2014-2015)
E - Research funding (personal).- Novartis : LCZ696 (2013)
Bang Lia Evi A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : Anti lipid drug (2013)
- Merck Sharp & Dohme : Anti lipid drug (2013)
- Astra Zeneca : Anti trombotic (2013)
- Amgen : Lipid lowering drug (2014)
- Astra Zeneca : Lipid lowering drug (2014)
- Merck Sharp & Dohme : Lipid lowering drug (2014)
- Amgen : Cardiovaskular (2015)
- Astra Zeneca : Cardiovaskular (2015)
- Bayer : Cardiovaskular (2015)
- Sanofi Aventis : Cardiovaskular (2015)
- Merck Sharp & Dohme : Cardiovaskular (2015)
- GSK : Cardiovaskular (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Anti lipid drug (2013)
- GlaxoSmithKline : Anti lipid drug (2013)
- Lilly : Anti lipid drug (2013)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
15/50
Barrabes Jose A A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Rovi : Antianginal agents (2013)
D - Research funding (departmental or institutional).- Astra Zeneca : Antiplatelet agents (2014-2015)
- GlaxoSmithKline : Participation in LATITUDE TIMI 60 study (losmapimod) (2015)
Baumgartner Helmut A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease (2013-2014-2015)
- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014-2015)
- Direct Flow Medical : transcatheter valve implantation (2013-2014-2015)
Becker David Nothing to be declared (2013)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Krka Pharma : Cardiology (2014-2015)
- Bayer Healthcare : Cardiology (2015)
Beishenkulov Medet Nothing to be declared (2013-2014-2015)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
16/50
Bolognese Leonardo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Eli Lilly, Daichhi Sankio, Abbott, Menarini, Astra : antiplatelet therapy, antianginal Rx, stents (2013-2014-2015)
D - Research funding (departmental or institutional).- Astra Zeneca : antiplatelet therapy (2013-2014-2015)
Budaj Andrzej A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : alirocumab (2013-2014-2015)
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
- Ferrer Internacional : Trinomia (polypill) (2015)
D - Research funding (departmental or institutional).- Astra Zeneca : Funding of TAN-SNIP observational study. No drugs involved (2015)
E - Research funding (personal).- Astra Zeneca : Ticagrelor (2013-2014-2015)
Bugiardini Raffaele Nothing to be declared (2013-2014-2015)
Carerj Scipione Nothing to be declared (2013-2014-2015)
Casselman Filip A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : Atrial fibrillation (2013-2014-2015)
- Edwards Lifesciences : Minimally invasive cardiac surgery (2013-2014-2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : Atrial fibrillation (2013-2014-2015)
- Edwards Lifesciences : Minimally invasive cardiac surgery (2013-2014-2015)
Chilingaryan Aram Nothing to be declared (2013-2014-2015)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
18/50
Cuisset Thomas A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medicines Company : Anticoagulant agent (2013)
- Eli Lilly : Antiplatelet (2013)
- Astra Zeneca : Antiplatelet Drug (2013)
- Daiichi Sankyo : Antiplatelet drug (2013)
- Iroko Cardio : Antiplatelet drug (2013)
- Biosensors : Device (2013)
- Boston Scientific : Device (2013)
- Terumo Inc : Device (2013)
- Abbott Vascular : Device (2013)
- Boston Scientific : DES (2014-2015)
- Biotronik : DES (2014-2015)
- Abbott Vascular : DES (2014-2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Clopidogrel (2014-2015)
- Eli Lilly : Prasugrel (2014-2015)
D - Research funding (departmental or institutional).- Eli Lilly : Medications (2013)
- Biomatrix : DES (2014-2015)
- Europa : Education (2014-2015)
- Bayer : Rivaroxaban (2014-2015)
- Hexacath : Stent (2014-2015)
- Edwards Lifesciences : TAVI (2014-2015)
- Astra Zeneca : Ticagrelor (2014-2015)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
19/50
Eftychiou Christos Nothing to be declared (2013-2014-2015)
Erol Cetin A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Hypertension (2013-2014-2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Menarini : Hypertension (2013-2014-2015)
Etriby Adel Mohamad Kamal
Nothing to be declared (2013-2014-2015)
Fitzsimons Donna Nothing to be declared (2013-2015)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : FH Tratment options (2014)
Gaemperli Oliver Nothing to be declared (2013)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Biosensors : Stents (2014)
- Biosensors : Axxess Bifurcation Stent (2015)
- Abbott Vascular : MitraClip (2015)
- Biosensors : Travel Grant to AsiaPCR 2015 (2015)
Ginghina Carmen Nothing to be declared (2013-2015)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- - LABORMED ALVOGEN (“Tabloul clinic al arteriopatiei periferice”) - ALFA WASSERMMAN (“Medicatia in arteriopatiile
Grosu Aurel Nothing to be declared (2013-2014-2015)
Gudnason Thorarinn Nothing to be declared (2015)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : NOAC (2014)
E - Research funding (personal).- Novartis : Heart failure (2013)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
20/50
Halle Martin A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Merck Sharp & Dohme : diabetes, prevention (2013)
- Berlin Chemie AG : diabetes, prevention (2013-2014)
- Sanofi Aventis : diabetes (2013-2014-2015)
- Novartis : heart failure (2014-2015)
- Merck Sharp & Dohme : lipids (2014-2015)
- Pfizer : coagulation (2015)
- Daiichi Sankyo : coagulation, diabetes (2015)
- Berlin Chemie AG : diabetes (2015)
- Roche Pharma : diabetes (2015)
- Techniker Krankenkasse : health insurance company (2015)
- Abbott : lipids (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Techniker Krankenkasse Hamburg : Health Insurance Company. Monitoring of Pilot Study (2013-2014)
Hamm Christian A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Iroko Cardio : drugs (2013)
- Roche Diagnostics : marker (2013)
- Medtronic : PCI (2013)
- Astra Zeneca : drugs (2013-2014-2015)
- Boehringer-Ingelheim : drugs (2013-2014-2015)
- Daiichi Sankyo : drugs (2013-2014-2015)
- Novartis : drugs (2013-2014-2015)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
D - Research funding (departmental or institutional).- Deutsche Forschungsgemeinschaft : experimental (2013-2014-2015)
- German Research Foundation : experimental studies (2013-2014-2015)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
22/50
Held Claes A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astrazeneca : cardiology (2013-2014-2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Roche Diagnostics : cardiology (2013-2014)
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
Iliodromitis Efstathios Nothing to be declared (2013-2014-2015)
James Stefan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : coagulation inhibition (2013-2014)
D - Research funding (departmental or institutional).- Astra Zeneca : Anti thrombotics (2015)
Kedev Sasko A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : Honaria (2013)
- Abbott Vascular : Speaker fees (2013)
- Boston Scientific : Speaker fees (2013-2014-2015)
- Meril : Speaker fees (2014)
- Medtronic : Speaker fees (2014-2015)
- Terumo Inc : Speaker fees (2015)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
24/50
Koning Rene Nothing to be declared (2013-2014)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Lilly : cardiology (2015)
- Abbott Vascular : cardiology (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Committee Member of CFCI (congres francophone Paris) : CARDIOLOGY (2015)
D - Research funding (departmental or institutional).- Biosensors : CARDIOLOGY (2015)
- Boston Scientific : CARDIOLOGY (2015)
- Biotronik : CARDIOLOGY (2015)
- Braun : CARDIOLOGY (2015)
Larsen Alf Inge Nothing to be declared (2013-2014-2015)
Latkovskis Gustavs A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Antiplatelets (2013)
- Berlin Chemie AG : Antihypertensive agents (2013-2014-2015)
- Merck Serono : Beta blockers (2013-2014-2015)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
25/50
Latkovskis Gustavs - University of Latvia : Education (2013-2014-2015)
- Latvian Research Institute of Cardiology : genetics of CVD, pharmacogenetics (2013-2014-2015)
- Siemens Healthcare : hs-troponin I (2013-2014-2015)
- Astra Zeneca : lipid-lowering drugs, anti platelets (2013-2014-2015)
- Servier : Hypertension, heart rate (2014-2015)
- Latvian Association of Human Genetics : Lecture on familial hypercholesterolemia (2015)
- Mylan : Lipid lowering therapies (2015)
D - Research funding (departmental or institutional).- Latvian Council of Science : Genetics of CVD (2013)
- Latvian Council of Science : Trimethylamine N-oxide and glucose metabolism; familial hypercholesterolemia. (2015)
E - Research funding (personal).- Bayer : Anticoagulation (2013)
- Merck Serono : bisoprolol and amlodipine combination (2013-2014-2015)
- Pharma and Chemistry Competence Centre of Latvia : Statin myopathy (2014-2015)
Lewis Basil S A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Anti-diabetics (2013)
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
26/50
Lewis Basil S - Sanofi Aventis : Lipidology (2013)
- Novartis : Heart failure (2013-2014-2015)
- Amgen : Lipidology (2013-2014-2015)
- Pfizer : Lipidology (2013-2014-2015)
- Astra Zeneca : Diabetes (2014-2015)
- Pfizer : Diabetes (2014-2015)
Lip Gregory Y H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astellas : atrial fibrillation, thrombosis (2013)
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
27/50
Matetzky Shlomi Nothing to be declared (2013-2014-2015)
Milicic Davor A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : cardiovascular drugs (2013-2014)
- Thoratec : mechanical circulatory support (2013-2014)
- Marck Medical : mechanical circulatory support (2013-2014)
D - Research funding (departmental or institutional).- University of Zagreb : Antithrombotic drugs (2015)
E - Research funding (personal).- University of Zagreb : Platelet reactivity to antithrombotic drugs (2013-2014)
Mimoso Jorge M Vieira A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Ivabradine (2013)
- JaBA Recordati : Pitavastatine (2014)
- Bayer : Xarelto (2014)
- Boehringer-Ingelheim : Dabigatrano (2015)
- Astra Zeneca : Ticagrelor (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Ticagrelor (2013)
Mourali Mohamed Sami Nothing to be declared (2013-2014-2015)
Mussagaliyeva Aisulu A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Stable angina (2013-2014)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
28/50
Mussagaliyeva Aisulu B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Stable angina (2013-2014-2015)
Najafov Ruslan Nothing to be declared (2013-2014-2015)
Nedeljkovic Milan Nothing to be declared (2013-2014-2015)
Neumann Franz Josef B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Antiplatelet therapy (2013-2014-2015)
Parkhomenko Alexander A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : trimetazidin, rivaroxaban, ticagrelor (2013-2014)
- BHFZ : corvitin (2015)
- Bayer Healthcare : rivaroxaban (2015)
- Astra Zeneca : ticagrelor (2015)
- Servier : trimetazidine (2015)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
29/50
Parkhomenko Alexander B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : rivaroxabane (2013-2014)
C - Receipt of royalties for intellectual property.- BHFZ : corvitine (2013-2014)
D - Research funding (departmental or institutional).- European Research Foundation FP7 : biomarkers (2015)
Pereira Bruno Nothing to be declared (2013)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Speaker Fees (2014)
- Abbott Vascular : Speaker Fees (2014)
- Merck Sharp & Dohme : Speaker Fees (2015)
Peters Ron J G Nothing to be declared (2013)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : anticoagulants (2014)
- Daiichi Sankyo : antiplatelet agents (2014)
- Amgen : lipid lowering (2014)
- Sanofi Aventis : lipid lowering (2014)
- Merck Sharp & Dohme : lipid lowering (2014)
- Astrazeneca : lipid lowering (2014)
- Sanofi Aventis : alirocumab (2015)
- Amgen : evolocumab (2015)
- Astrazeneca : ticagrelor (2015)
D - Research funding (departmental or institutional).- Philips Healthcare : DirectLife activity program (2015)
- weight watchers international : weight reduction and physical fitness (2015)
Piepoli Massimo Francesco Nothing to be declared (2013-2014-2015)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
30/50
Pietila Mikko Juhani A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- St Jude Medical : Invasive cardiology (2013)
Richter Dimitrios A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Menarini : CAD (2013)
- Novartis : hypertension (2013-2014-2015)
- Abbott : Lipids (2013-2014-2015)
- Amgen : lipids (2013-2014-2015)
- Unilever : lipids (2013-2014-2015)
- Merck Sharp & Dohme : lipids (2013-2014-2015)
- Vianex : lipids (2013-2014-2015)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
Rickli Hans A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : Dabigatran (2013)
- Daiichi Sankyo : Prasugrel (2013-2014)
- Servier : Ivabradin (2013-2014-2015)
- Bayer Healthcare : Rivaroxaban (2013-2014-2015)
- Astra Zeneca : Ticagrelor (2013-2014-2015)
Rosemann Thomas A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Menarini : general internal medicine (2013-2014)
- Novartis : Lecture about personalized medicine (2014)
- Menarini : Hypertension (2015)
D - Research funding (departmental or institutional).- Menarini : Hypertension (2015)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
32/50
Sechtem Udo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : Drugs (2013-2014)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Berlin Chemie AG : Drugs (2013)
- Astra Zeneca : Drugs (2013-2014)
- Pfizer : Drugs (2013-2014)
- Siemens Healthcare : Drugs (2013-2014)
- Bayer Vital : Drugs (2013-2014)
- Boehringer-Ingelheim : Drugs (2013-2014-2015)
- Bayer Healthcare : Drugs (2013-2014-2015)
- Berlin Chemie AG : cath lab equipment (2014)
- Bristol Myers Squibb : Drugs (2015)
Serpytis Pranas D - Research funding (departmental or institutional).- European Research Foundation FP7 : CULPRIT-SHOCK study, National Investigator (2013-2014-2015)
Sinnaeve Peter R B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : ACS (2013)
- GlaxoSmithKline : ACS & CAD (2013)
- Abbott Vascular : PCI (2013)
- Lilly : ACS (2013-2014-2015)
- Bayer : ACS & AF (2013-2014-2015)
- Boehringer-Ingelheim : ACS & AF (2013-2014-2015)
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
33/50
Sinnaeve Peter R - GlaxoSmithKline : ACS & CAD, trials (2014-2015)
- Astra Zeneca : ACS, trials (2014-2015)
- Novartis : trials (2014-2015)
D - Research funding (departmental or institutional).- Astra Zeneca : basic science and epidemiology (2013-2014-2015)
- Flemish Government : basic science (2014-2015)
Steg Philippe Gabriel A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : Contrast agents (2013)
- Lilly : antithrombotics and lipid lowering drugs (2013-2014-2015)
- Amarin : Lipid compounds (2013-2014-2015)
- Medtronic : stents (2013-2014-2015)
- Regado Biosciences : Steering Committee for trial of anticoagulant (2014)
- Janssen-Cilag : antithrombotics (2015)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
34/50
Steg Philippe Gabriel - Novartis : consulting (2015)
- Pfizer : Events adjudication committee (2015)
- CSL Behring : lipid lowering drugs (2015)
C - Receipt of royalties for intellectual property.- Aterovax : Biomarkers (2013-2014-2015)
D - Research funding (departmental or institutional).- Sanofi Aventis : Clinical trial on lipids (2013-2014-2015)
- Servier : Registry on coronary artery disease (2013-2014-2015)
Studencan Martin A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- GlaxoSmithKline : Dabigatran (2013)
- MSD : Esetimibe, Inegy (2013-2014-2015)
Swanson Neil Nothing to be declared (2013)
D - Research funding (departmental or institutional).- Astra Zeneca : Antiplatelet drugs (ATLANTIC trial) (2014-2015)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Preduktal - Investigator in ATPCI study (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sadra Medical : Odyssey study (2015)
Tsioufis Costas Nothing to be declared (2013)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Honoraria, Travel Expenses (2014-2015)
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
36/50
Weidinger Franz - Sanofi Aventis : Lipid lowering (2014-2015)
D - Research funding (departmental or institutional).- Terumo Inc : Drug-eluting stent (2015)
Widimsky Petr A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Antithrombotic agents (2013-2014)
- Eli Lilly : Antithrombotic agents (2013-2014-2015)
- Abbott : Stents (2013-2014-2015)
- Medtronic : Stents (2013-2014-2015)
Zamorano Gomez Jose Luis
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichii : Atrial Fib (2013)
- Merck Sharp & Dohme : Lipid Lowering (2013)
- Philips : 3D echo (2014)
- Toshiba medical imaging : fusion imaging 3D echo CT (2014)
- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)
- MSD : CV risk factors (2014-2015)
- Abbott : Lecturing (2015)
- Astra Zeneca : Lecturing (2015)
- Pfizer : Lecturing (2015)
- Sorin Group : Respicardia echo protocol (2015)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
37/50
Zamorano Gomez Jose Luis
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- European Research FP7 : CV Imaging (2013)
- Servier : Imaging in ISchemic patients (2013)
- Siemens Healthcare : 3d echo software and free style echo (2014-2015)
- Toshiba medical imaging : Fusion Imaging (2015)
C - Receipt of royalties for intellectual property.- Springer : ESC Textbook of CV Imaging (2013)
D - Research funding (departmental or institutional).- Amgen : Clinical trial (2014-2015)
- Novartis : Clinical trial (2014-2015)
- Ikaria : Clinical trial (2014-2015)
27/08/2015
Guidelines on NSTE-ACS (version 2015) - Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
38/50
Aboyans Victor Nothing to be declared (2013)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Antithrombotics (2014)
Achenbach Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : Anticoagulation (2013)
- Behring : Anticoagulation (2013)
- Astra Zeneca : Antiplatelet Therapy (2013)
- Abbott : Coronary Intervention (2013)
- Siemens Healthcare : CT (2013)
- Servier : Imaging (2013)
- Guerbet : Imaging (2013)
D - Research funding (departmental or institutional).- Abbott : Coronary Intervention (2013-2014)
- Siemens Healthcare : Imaging (2013-2015)
Agewall Stefan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Böhringer Ingelheim : Anticoagulatn treatment (2013)
- Roche Diagnostics : Cardiac markers (2013)
- Orion : Heart failure (2013)
27/08/2015
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
D - Research funding (departmental or institutional).- Biotronik : Vasovagal syncope & Pacing (2013)
- Bayer : Anticoagulation (2015)
27/08/2015
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
40/50
Baumgartner Helmut A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease (2013-2014-2015)
- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014-2015)
- Direct Flow Medical : transcatheter valve implantation (2013-2014-2015)
Bax Jeroen Nothing to be declared (2014-2015)
D - Research funding (departmental or institutional).- Servier : Farma (2013)
- Edwards Lifesciences : Heart Valves (2013)
- GE Healthcare : Imaging (2013)
- Lantheus Inc : Imaging (2013)
- Boston Scientific : Pacing (2013)
- Medtronic : Pacing (2013)
- St Jude Medical : Pacing (2013)
- Biotronik : Pacing (2013)
Bueno Hector A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- BMS/Pfizer : Apixaban (2013)
27/08/2015
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
- Ferrer Internacional : Trinomia (polypill) (2015)
D - Research funding (departmental or institutional).- Astra Zeneca : Funding of TAN-SNIP observational study. No drugs involved (2015)
E - Research funding (personal).- Astra Zeneca : Ticagrelor (2013-2014-2015)
Carerj Scipione Nothing to be declared (2013-2014-2015)
Erol Cetin A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Hypertension (2013-2014-2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Menarini : Hypertension (2013-2014-2015)
27/08/2015
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
42/50
Fitzsimons Donna Nothing to be declared (2013-2015)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : FH Tratment options (2014)
Gaemperli Oliver Nothing to be declared (2013)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Biosensors : Stents (2014)
- Biosensors : Axxess Bifurcation Stent (2015)
- Abbott Vascular : MitraClip (2015)
- Biosensors : Travel Grant to AsiaPCR 2015 (2015)
Kirchhof Paulus A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2013)
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
43/50
Kirchhof Paulus B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : cardiovascular (2013)
- Bayer Healthcare : cardiovascular (2013)
- Gilead : cardiovascular (2013)
- BMS / Pfizer alliance : cardiovascular (2013)
D - Research funding (departmental or institutional).- St Jude Medical : cardiovascular (2013-2014-2015)
- European Union horizon2020 : cardiovascular (2014-2015)
- German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular (2014-2015)
Kolh Philippe H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- B.Braun : Surgical instruments (2013-2014)
D - Research funding (departmental or institutional).- St Jude Medical : Cardiac valves (2013)
- Boston Scientific : Coronary stents (2013)
- Siemens Healthcare : Medical imaging (2013)
- Johnson & Johnson : Thoracoscopic devices (2013)
27/08/2015
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
44/50
Kolh Philippe H - Edwards Lifesciences : Cardiac valves (2013-2014-2015)
- Medtronic : Cardiac valves (2013-2014-2015)
Lancellotti Patrizio A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Heart Failure (2013)
- Abbott : MitraClip (2013)
- Menarini : nebivolol (2014)
- St Jude Medical : Heart Failure (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astrazeneca : Dyslipidemia (2013)
- Boston Scientific : CRT (2014)
- Servier : procoralan (2014)
- Daiichi Sankyo : Teaching course on imaging (2015)
D - Research funding (departmental or institutional).- Actelion : Pulmonary Hypertension (2013)
Lip Gregory Y H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astellas : atrial fibrillation, thrombosis (2013)
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
45/50
Lip Gregory Y H D - Research funding (departmental or institutional).- Bayer : atrial fibrillation, thrombosis (2013)
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
46/50
Ponikowski Piotr - Astra Zeneca : acute coronary syndrome (2014-2015)
D - Research funding (departmental or institutional).- Vifor Pharma ltd : heart failure (2013)
- Singulex : biomarkers (2015)
27/08/2015
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
47/50
Roffi Marco A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichi Sankyo : antiplatelet therapy (2013)
- Lilly : antiplatelet therapy (2013)
- Astra Zeneca : antipletelet therapy (2013)
- Johnson & Johnson : coronary catheters (2014)
D - Research funding (departmental or institutional).- Biosensors : devices (2013-2014-2015)
- Boston Scientific : devices (2013-2014-2015)
- Medtronic : devices (2013-2014-2015)
- Biotronik : devices (2013-2014-2015)
- Abbott Vascular : devices (2013-2014-2015)
Torbicki Adam A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bristol Myers Squibb : Pulmonary arterial hypertension (2013-2014-2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer Healthcare : Pulmonary hypertension (2013-2014-2015)
Vaz Carneiro Antonio Nothing to be declared (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- AbbVie : Oncology (2013-2014)
Windecker Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Antiplatelet drug (2013)
- Eli Lilly : Antiplatelet drug (2013)
27/08/2015
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
48/50
Windecker Stephan - Abbott : Stent (2013)
- Medtronic : Stent (2013)
- Biotronik : Stent (2013)
- Astra Zeneca : Antiplatelet therapy (2014-2015)
- Eli Lilly : Antiplatelet therapy (2014-2015)
- Bayer Healthcare : Antithrombotic drug (2014-2015)
- Abbott : Stent and Heartvalvetherapy (2014-2015)
D - Research funding (departmental or institutional).- St Jude Medical : OCT (2013-2014-2015)
- Biotronik : Stent (2013-2014-2015)
- Medtronic : Stent and Heartvalves (2014)
- Medicines Company : Antithrombotic therapy (2014-2015)
- Johnson & Johnson : Catheters (2014-2015)
- Edwards Lifesciences : Heartvalves (2014-2015)
- Abbott : Stent (2014-2015)
- Boston Scientific : Stent and Heartvalves (2014-2015)
Zamorano Gomez Jose Luis
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichii : Atrial Fib (2013)
- Merck Sharp & Dohme : Lipid Lowering (2013)
27/08/2015
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
49/50
Zamorano Gomez Jose Luis
- Philips : 3D echo (2014)
- Toshiba medical imaging : fusion imaging 3D echo CT (2014)
- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)
- MSD : CV risk factors (2014-2015)
- Abbott : Lecturing (2015)
- Astra Zeneca : Lecturing (2015)
- Pfizer : Lecturing (2015)
- Sorin Group : Respicardia echo protocol (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- European Research FP7 : CV Imaging (2013)
- Servier : Imaging in ISchemic patients (2013)
- Siemens Healthcare : 3d echo software and free style echo (2014-2015)
- Toshiba medical imaging : Fusion Imaging (2015)
C - Receipt of royalties for intellectual property.- Springer : ESC Textbook of CV Imaging (2013)
D - Research funding (departmental or institutional).- Amgen : Clinical trial (2014-2015)
- Novartis : Clinical trial (2014-2015)
- Ikaria : Clinical trial (2014-2015)
27/08/2015
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.